Relay Therapeutics reports Q1 2026 results, FDA grants breakthrough status to breast cancer drug zovegalisib

Relay Therapeutics announced its Q1 2026 financial results and key updates, including FDA granting Breakthrough Therapy designation to its drug zovegalisib for PIK3CA-mutant advanced breast cancer. The company reported promising clinical data showing an 11.1-month median progression-free survival in heavily pre-treated breast cancer patients and plans to start a Phase 3 frontline trial in early 2027. Relay also initiated a Phase 1/2 trial for RLY-8161 targeting NRAS-mutant tumors and expects initial vascular anomalies data in May 2026. With $642 million in cash, the company is well-funded to continue its clinical programs through 2029.